Page 1 of 5

FOR PROFESSIONAL USE ONLY

Total IGF-I ELISA IVD

AL-121
INTENDED USE can now be measured in individual subjects using the Ansh Free IGF-I Kit AL-
The Total IGF-I enzyme linked immunosorbent assay (ELISA) kit provides 122 along with the Total IGF-I kit.
materials for the quantitative measurement of IGF-I in serum, plasma and
other biological fluids. This assay is intended for in vitro Diagnostic Use Only. PRINCIPLE OF THE TEST
The Total IGF-I is a quantitative one-step sandwich type immunoassay. In the
SUMMARY AND EXPLANATION first step Calibrators, Controls and unknown samples are added to IGF-I
antibody coated microtiter wells and incubated along with horseradish
IGF-I, also known as somatomedin C, is a 7.6 kDa, 70 amino acid residue
peroxidase labeled antibody conjugate. After a washing step, the wells are
peptide, which mediates the actions of growth hormone (GH).1 IGF-I is
incubated with substrate solution (TMB). After TMB incubation, an acidic
synthesized as a prohormone, a polypeptide consisting of A, C, B, D, and E
stopping solution is added. In principle, the antibody-HRP conjugate binds to
domains.1,2 After post-translational modification, the mature IGF-I consists of
the solid phase antibody-antigen complex. Finally, the antibody-antigen-
the A, C, B and D domains, and is structurally homologous to IGF-II and insulin.
conjugate complex bound to the well is detected by addition of enzyme-

ns h
In vivo, IGF-I is secreted by the liver and several other tissues and is postulated

ci de nly
substrate reaction. The degree of enzymatic turnover of the substrate is

io it
to have mitogenic and metabolic actions at or near the sites of synthesis; this

at w
determined by dual wavelength absorbance measurement at 450 nm as

.
has been termed the paracrine role of IGF-I.1 IGF-I also appears in the

pe clu O
primary test filter and 630 nm as reference filter. The absorbance measured is

fic d
peripheral circulation where it circulates primarily in a high molecular weight
directly proportional to the concentration of IGF-I in the samples and

t s t in es
tertiary complex with IGF-binding protein-3 (IGFBP-3) and acid-labile subunit
calibrators.
(ALS).2,3 A smaller proportion of IGF-I may circulate in association with other
ac er os
IGF-binding proteins.3 It has been estimated that <5% of plasma IGF-I
ex ins rp

circulates unbound.4 In vivo synthesis of IGF-I is stimulated by GH, and is also MATERIALS SUPPLIED
or e Pu

dependent on other factors, including adequate nutrition.1,5 IGF-I may inhibit CAL-121A - CAL-121F IGF-I Calibrators A - F
pituitary production of GH; however, a feedback mechanism has not been Six vials, 0.5 mL, labeled A-F, containing concentrations of Human IGF-I in the
t f ag e

completely defined. range of 0 to 50ng/mL (Refer to Calibration Card for exact values), in buffer
uc ck tiv

with Pro-Clean 400. Store unopened at 0 to -20°C until the expiration date.
od a tra

In humans, plasma IGF-I levels are low during fetal and neonatal life, increase
Avoid repeated freeze thaws.
gradually during childhood, peak during mid-puberty, and decline gradually
NOTE: The calibrators are traceable to World Health Organization IGF-I
pr to p lus

through adult life.1,5-7 Average plasma IGF-I levels are slightly higher in females
preparation NIBSC code 02/254, version 6.0.
at each age. Maternal plasma levels increase during pregnancy.1 Plasma IGF-I
l
th er r I

levels are stabilized by the IGF-binding proteins and there is negligible diurnal
CTR-121-I & CTR-121-II IGF-I Controls I & II
ef Fo

variation.5 Plasma IGF-I levels are low relative to age- and sex-related norms
Two vials, 0.5 mL, labeled Levels I and II containing low and high IGF-I
in GH deficiency5-7, malnutrition5,8 and in the syndrome of GH-receptor
concentrations (Refer to Calibration Card for exact values) in buffer with Pro-
deficiency (Laron dwarfism).9 Abnormally low levels of plasma IGF-I have been
Clean 400. Store unopened at 0 to -20°C until the expiration date. Avoid
used as a diagnostic indicator of GH deficiency, although a significant
repeated freeze thaws.
proportion of GH-deficient children may have IGF-I levels in the normal range,
R
e

and normal short children may have low IGF-I levels.1,6,7 Plasma IGF-I levels
PLT-121 IGF-I Coated Microtitration strips
may also be used to monitor the short- and long-term in vivo responses to GH
One strip holder, containing 12 strips and 96 microtitration wells with IGF-I
treatment.5 Abnormally elevated IGF-I levels in acromegaly (GH excess) may
antibody immobilized to the inside wall of each well. Store at 2-8°C until
be used as a diagnostic tool and to monitor treatment.1,5
expiration date in the resealable pouch with a desiccant to protect from
moisture.
Assay of plasma IGF-I is complicated by the presence of IGF-binding proteins,
which may sequester IGF-I in the reaction mixture.1 Various methods have
ECR-121 IGF-I Enzyme Conjugate Ready-To-Use (RTU)
been devised to separate the IGF and IGF-binding proteins prior to assay. Size-
One bottle, 12 mL, containing HRP-conjugated IGF-I antibody in buffer with a
exclusion gel chromatography in acid is considered to be optimal1,10, but this
non-mercury preservative. Store at 2-8°C until expiration date.
procedure is not feasible for routine use. Acidification followed by ethanol
precipitation of the IGFBP fraction1,11 gives results which are similar to acid-
SPB-121-I IGF-I Sample Buffer I
chromatography. SepPak C-18 cartridges are less convenient11 and give
One bottle, 25 mL, containing sample buffer I with a non-mercury
variable results and relatively low recovery.
preservative. Store unopened at 2 to 8°C until the expiration date.
The Ansh Labs Total IGF-I Assay uses an acidification and neutralization
SPB-121-II IGF-I Sample Buffer II
method to dissociate IGF-I from all the binding proteins. IGF-I levels are
One bottle, 25 mL, containing sample buffer II with a non-mercury
quantified in the extracted samples using a highly sensitive and specific
preservative. Store unopened at 2 to 8°C until the expiration date.
enzyme-linked immunosorbent assay. Also, a ratio of Free IGF-I to Total IGF-I

Document No: IFU.AL.121 Revision No: 09 Release Date: 08/03/2022 TOTAL IGF-I ELISA IVD
 Page 2 of 5

TMB-100 TMB Chromogen Solution PROCEDURAL NOTES

One bottle, 12 mL, containing a solution of tetramethylbenzidine (TMB) in 1. A thorough understanding of this package insert is necessary for
buffer with hydrogen peroxide. Store at 2-8°C until expiration date. successful use of the Total IGF-I ELISA assay. It is the customer’s
responsibility to validate the assay for their use. Accurate results will only
STP-100 Stopping Solution be obtained by using precise laboratory techniques and following the
One bottle, 12 mL, containing 0.2 M sulfuric acid. Store at 2 to 30°C until package insert.
expiration date. 2. A calibration curve must be included with each assay.
3. Bring all kit reagents to room temperature before use. Thoroughly mix
WSH-100 Wash Concentrate A the reagents before use by gentle inversion. Do not mix various lots of
One bottle, 60 mL, containing buffered saline with a nonionic detergent. Store any kit component and do not use any component beyond the expiration
at 2 to 30°C until expiration date. Dilute 25-fold with deionized water prior to date.
use. 4. Use a clean disposable pipette tip for each reagent, calibrator, control,
or sample. Avoid microbial contamination of reagents, contamination of
MATERIALS REQUIRED BUT NOT PROVIDED the substrate solutions with the HRP conjugates. The enzyme used as the
1. Microtitration plate reader capable of absorbance measurement at 450 label is inactivated by oxygen, and is highly sensitive to microbial
nm, 405 nm, and 630 nm. contamination, sodium azide, hypochlorous acid and aromatic
2. Microplate shaker. chlorohydrocarbons often found in laboratory water supplies. Use
3. Microplate washer. deionized water.
4. Semi-automated/manual precision pipette to deliver 10–250 μL. 5. Incomplete washing will adversely affect the outcome and assay
5. Vortex mixer. precision. Care should be taken to add TMB into the wells to minimize

ns h
6. Deionized water. potential assay drift due to variation in the TMB incubation time. Avoid

ci de nly
io it
7. Disposable 12 x 75 mm culture tubes. exposure of the reagents to excessive heat or direct sunlight.

at w
.
pe clu O
fic d
WARNINGS AND PRECAUTIONS PREPARATION OF REAGENTS
For in vitro Diagnostic Use Only.
t s t in es 1. Wash Solution: Dilute wash concentrate 25-fold with deionized water.
ac er os
The following precautions should be observed: The wash solution is stable for one month at room temperature when
ex ins rp

a) Follow good laboratory practice. stored in a tightly sealed bottle.

b) Use personal protective equipment. Wear lab coats and disposable 2. Microtitration Wells: Select the number of coated wells required for the
or e Pu

gloves when handling immunoassay materials. assay. The remaining unused wells should be placed in the resealable
c) Handle and dispose of all reagents and material in compliance with pouch with a desiccant. The pouch must be resealed to protect from
t f ag e
uc ck tiv

applicable regulations. moisture.

od a tra

WARNING: Potential Biohazardous Material SAMPLE PREPARATION

pr to p lus

Handle all reagents and patient samples at a Biosafety Level 2, as SAMPLE PREPARATION (1:25 dilution):
recommended for any potentially infectious human material in the Centers for a) For each unknown sample, label one 12x75mm culture tube
l
th er r I

Disease Control/National Institutes of Health manual "Biosafety in appropriately and add 240 µL of IGF-I Sample Buffer I.
ef Fo

Microbiological and Biomedical Laboratories," 5th Edition, 200712. b) Pipette 20 µL of each sample into the appropriate pre-labeled tubes.
c) Place the tubes in a tight-fitting tube rack and shake at a slow speed (300-
WARNING: Potential Chemical Hazard 400 rpm) at room temperature (23 ± 2°C) for 30 minutes.
Some reagents in this kit may contain Pro-Clean 400 and Sodium azide13 as a d) Pipette 240 µL of IGF-I Sample Buffer II into each tube and shake at a
slow speed (300-400 rpm) at room temperature (23 ± 2°C) for 10
R

preservative. Pro-Clean 400 and Sodium azide in concentrated amounts are

e

irritants to skin and mucous membranes. minutes.

For further information regarding hazardous substances in the kit, please refer e) Vortex well. The samples are now ready to be assayed.
to the MSDS, either at AnshLabs.com or by request. NOTE: Calibrators and controls should NOT be treated with the Sample Buffers.

SAMPLE COLLECTION ASSAY PROCEDURE

a) Serum or plasma is the recommended sample type. Allow all specimens and reagents to reach room temperature and mix
b) Sample handling, processing, and storage requirements depend on the thoroughly by gentle inversion before use. Calibrators, controls, and
brand of blood collection tube that you use. Please reference the unknowns should be assayed in duplicate.
manufacturer’s instructions for guidance. Each laboratory should 1. Prepare all samples to be assayed as per the “Sample Preparation”
determine the acceptability of its own blood collection tubes and serum section of this package inserts.
separation products. NOTE: Any sample reading higher than the highest calibrator should be
c) Samples should be stored frozen at -20°C or lower. diluted and reassayed. (See the “Linearity” section for dilution protocol).
d) Avoid repeated freezing and thawing of samples. NOTE: Calibrators and controls should NOT be treated with the Sample
e) Avoid assaying lipemic, hemolyzed or icteric samples. Buffers.
f) For shipping, place specimens in leak proof containers in biohazard 2. Label the microtitration strips to be used.
specimen bags with appropriate specimen identification and test 3. Pipette 50 µL each of the Calibrators, Controls and Unknowns from step
requisition information in the outside pocket of the biohazard specimen 1 to the appropriate wells.
bag. Follow DOT and IATA requirements when shipping specimens.

Document No: IFU.AL.121 Revision No: 09 Release Date: 08/03/2022 TOTAL IGF-I ELISA IVD
 Page 3 of 5

4. Add 100 µL of the IGF-I Enzyme Conjugate-RTU to each well using a REPRESENTATIVE CALIBRATION CURVE DATA
repeater pipette.
Conc.
5. Incubate the plate, shaking at a fast speed (600-800 rpm) on an orbital Well Number Calibrators Mean Absorbance
(ng/mL)
microplate shaker, for 60 minutes at room temperature (23 ± 2°C).
A1, A2 A 0.026 (Blank) 0
6. Aspirate and wash each strip 5 times with Wash Solution (350 µL/per
B1, B2 B 0.034 0.9
well) using an automatic microplate washer.
C1, C2 C 0.12 2.8
7. Add 100 μL of the TMB chromogen solution to each well using a repeater
D1, D2 D 0.50 8.6
pipette. Avoid exposure to direct sunlight.
E1, E2 E 1.46 21.0
8. Incubate the wells, shaking at 600–800 rpm on an orbital microplate
F1, F2 F 3.35 50.0
shaker, for 8-10 min at room temperature (23 ± 2°C).
CAUTION: The above data must not be employed in lieu of data obtained by
NOTE: Visually monitor the color development to optimize the incubation
the user in the laboratory
time.
9. Add 100 μL of the Stopping solution to each well using a repeater
pipette. Read the absorbance of the solution in the wells within 10 ANALYTICAL CHARACTERISTICS
minutes, using a microplate reader set to 450 nm. All concentrations listed are in ng/mL.
NOTE: Zero calibrator should be programmed as “Blank” while reading
the optical density. If instrument has a wavelength correction, set the Imprecision:
instrument to dual wavelength measurement at 450 nm with Reproducibility of the Total IGF-I assay was determined using two kit controls
background wavelength correction at 630 nm. and one serum pool sample (n=24 for all). The study included six assays with
samples CI, CII, QC1 in replicates.

ns h
RESULTS Sample Mean Conc. Within Run Between Run Total

ci de nly
io it
NOTE: The results in this package insert were calculated by plotting the ID (ng/mL) SD %CV SD %CV SD %CV

at w
.
pe clu O
log optical density (OD) data on the y-axis and log IGF-I concentration CI 2.087 0.086 4.14 0.100 4.81 0.132 6.35

fic d
on X-axis using a cubic regression curve-fit. Alternatively, log vs. log CII 8.191 0.350 4.27 0.341 4.17 0.489 5.97

t s t in es
quadratic regression curve-fit can be used. Other data reduction methods QC1 132.207 2.166 1.64 5.410 4.09 5.827 4.41
ac er os
may give slightly different results.
1. Calculate the mean optical density (OD) for each calibrator, Control, or Analytical Sensitivity:
ex ins rp

Unknown. The analytical sensitivity in the Total IGF-I assay, as calculated by the
or e Pu

2. Plot the log of the mean OD readings for each of the Calibrators along interpolation of mean plus two standard deviations of 20 replicates of
the y-axis versus log of the IGF-I concentrations in ng/mL along the x- calibrator A (0 ng/mL) and calibrator B (0.48 ng/mL), is 0.025 ng/mL.
t f ag e

axis, using a cubic regression or polynomial degree 3 curve-fit.

uc ck tiv

3. Determine the IGF-I concentrations of the Controls and diluted Analytical Specificity:
od a tra

unknowns from the calibration curve by matching their mean OD The monoclonal antibody pair used in the assay detects IGF-I. Other related
readings with the corresponding IGF-I concentrations.
pr to p lus

analytes at the concentration in the table below did not show any significant
4. The measured concentrations of the unknown samples should be cross-reaction when run neat (untreated).
l

multiplied by the dilution factor (25 folds).

th er r I

Sample Concentration
Cross-reactant % Cross-reactivity
5. Any sample reading lower than the analytical sensitivity should be No. (ng/mL)
ef Fo

reported as such. 1 IGFBP-2 1000 ND

6. Any sample reading higher than the highest calibrator should be diluted 2 IGFBP-3 1000 0.04
further and reassayed. (See the “Linearity” section for dilution protocol). 3 IGFBP-4 1000 ND
Multiply the measured concentrations in ng/mL by the appropriate 4 IGFBP-5 1000 ND
R

dilution factor.
e

5 Rat IGF-I 1000 3.16

6 IGF-I/IGFBP-3 complex 1000 0.42
LIMITATIONS 7 IGF-II 1000 ND

The reagents supplied in this kit are optimized to measure Total IGF-I levels in
serum. If there is evidence of microbial contamination or excessive turbidity in Interference:
a reagent, discard the vial. For assays employing antibodies, the possibility When potential interferents (hemoglobin, triglycerides, and bilirubin) were
exists for interference by heterophilic antibodies in the samples.14 added at the specified concentrations to control samples, Total IGF-I
concentration was within ±12% of the control as represented in the following
QUALITY CONTROL table.
Analyte Unspiked Spiked Sample
• Each laboratory should establish mean values and acceptable ranges to %
Interferents Conc. Sample Value Value
assure proper performance. Difference
(mg/mL) (ng/mL) (ng/mL)
• Each laboratory should establish internal Total IGF-I control ranges. The 54.73 50.25 -8.177
results should fall within established confidence limits. Hemoglobin 1.35 83.63 91.13 8.969
• A full calibration curve, and controls, should be included in each assay. 125.8 115.8 -7.893
• TMB should be colorless. Development of any color may indicate reagent 54.73 61.15 11.74
Triglycerides 5 83.63 91.23 9.148
contamination or instability.
125.8 132.0 4.950
54.83 56.35 2.782
Bilirubin 0.5
87.65 92.00 4.963

Document No: IFU.AL.121 Revision No: 09 Release Date: 08/03/2022 TOTAL IGF-I ELISA IVD
 Page 4 of 5

128.9 125.0 -3.044 Method Comparison:

The Ansh Total IGF-I ELISA has been compared to Mediagnost IGF-I ELISA (E20)
Inhibition: assay (Method A) using 36 samples in the range of 63 ng/mL to 1162 ng/mL.
Various concentrations of IGFBP-3 were spiked into IGF-I and incubated for 30 Passing Bablok analysis of the results yielded the following Regression: Total
minutes to allow for the IGF-I/IGFBP-3 complex to form. The following table IGF-I ELISA (AL-121) = 0.93 (Method A) + 52.21 (r=0.97; P<0.0001).
outlines the results.
Sample IGFBP-3: IGF-I 1200
% Recovery of IGF-I % Inhibition of IGF-I
No Concentration
1000

Ansh Total IGF-I

1 31: 1 2.4 97.6
2 15.6: 1 15.4 84.6 800

3 7.8: 1 63.2 36.8 600

4 3.1: 1 97 3
400

200
Linearity:
Three samples were used to study sample linearity. Each sample was 0
0 200 400 600 800 1000 1200
independently treated at 1:25, 1:50 and 1:100 as per the “Sample Preparation” Method A
section. For the 1:25 dilution, 20ul of sample was added to 240ul of Sample
Buffer I in the first step and then 240ul of Sample Buffer II was added in the
second step. For the 1:50 dilution, 10ul of sample was added to 245ul of The Ansh Total IGF-I ELISA has also been compared to IDS-iSYS IGF-I assay
Sample Buffer I in the first step and then 245ul of Sample Buffer II was added (Method B) using 45 samples in the range of 32.3 ng/mL to 265.0 ng/mL.

ns h
in the second step. For the 1:100 dilution, 10ul of sample was added to 495ul Passing Bablok analysis of the results yielded the following Regression: Total

ci de nly
io it
of Sample Buffer I in the first step and then 495ul of Sample Buffer II was added IGF-I ELISA (AL-121) = 1.81 (Method B) – 26.54 (r=0.957).

at w
.
pe clu O
in the second step. The % recovery on the individual dilutions is represented

fic d
in the following table: Expected Values:

t s t in es
Treatment Expected Conc. Observed %
Male and Female serum samples were analyzed using Ansh Total IGF-I ELISA.
Sample
Dilution Factor (ng/mL) Conc. (ng/mL) Recovery The expected ranges were calculated on these samples using 95% non-
ac er os
1:25 8.153 NA NA parametric estimation using Analyse-It® for Microsoft Excel.
ex ins rp

1 1:50 4.077 4.142 102% Number Median Total IGF-I

Median
Sample of Total IGF-I Reference Range
or e Pu

1:100 2.038 1.878 92% Age

specimens (ng/mL) (ng/mL)
1:25 20.483 NA NA
Females (12-25yrs) 12 18 463.76 118.76 – 822.13
t f ag e

2 1:50 10.242 9.222 90%

Females (26-50yrs) 35 32 209.18 48.75 – 407.37
uc ck tiv

1:100 5.121 4.504 88%

Females (51-90yrs) 32 66 189.25 46.24 – 317.17
od a tra

1:25 10.686 NA NA
Males (2-25yrs) 13 17 355.83 231.32 – 406.70
3 1:50 5.343 4.446 83%
Males (26-50yrs) 38 37 244.73 105.40 – 400.90
pr to p lus

1:100 2.672 2.476 93%

Males (51-90yrs) 26 67 203.21 68.00 – 325.50
l
th er r I

Treated Sample Stability: The expected ranges for Total IGF-I in pediatric male samples in the age range
ef Fo

Sample stability has been studied with eight samples prepared as per the of 3.0 – 18.0 years were calculated using 95% non-parametric estimation. A
“Sample Preparation” section. These eight samples were assayed at 0 hour total of 404 samples in Pubic Hair Tanner stages 1 - 5 were evaluated using
and 4-hour intervals after preparation. Regression analysis yielded the Analyse-It® for Microsoft Excel as seen in table below.
following equation: 4hr = 0.95(0hr) + 0.02 (R2 = 0.99) Pubic Hair Number of Median Conc. Total IGF-I (ng/mL)
Tanner Stage specimens (n) (ng/mL) 95% CI
R
e

30 1 218 225.3 91.2 - 558.8

25 2 54 387.9 149.3 - 809.5
Samples at 4 hr

20 3 32 650.9 299.5 - 1053.9

15 4 50 713.3 430.2 - 1051.6

5 50 636.6 389.5 - 1001.8
10
5 The expected ranges for Total IGF-I in pediatric female samples in the age
0 range of 2.4 – 18.0 years were calculated using 95% non-parametric
0 10 20 30 estimation. A total of 432 samples in Breast Tanner stages 0 - 5 were evaluated
Samples at 0hr using Analyse-It® for Microsoft Excel as seen in table below.
Sample Type: Breast Tanner Number of Median Conc. Total IGF-I (ng/mL)
Fifty-two matched Serum, Lithium heparin plasma and Potassium EDTA Stage specimens (n) (ng/mL) 95% CI
0 15 186.7 86.4 - 519.8
plasma specimens in the range of 26-400 ng/mL were compared in the Ansh
Total IGF-I assay. 1 174 266.0 106.2 - 534.2

Passing Bablok analysis of the results yielded the following regressions: 2 61 384.2 195.3 - 1022.6

1. Lithium Heparin Plasma = 0.87(Serum) - 5.36, (r=0.85; P<0.0001) 3 58 817.3 477.0 - 1089.6

2. Potassium EDTA Plasma = 0.86(Serum) - 5.61, (r=0.85; P<0.0001) 4 53 711.2 348.5 - 1135.7

3. Potassium EDTA Plasma = 1.00(Lithium hep)- 0.45, (r=0.87; P<0.0001) 5 71 619.5 270.1 - 979.6

Document No: IFU.AL.121 Revision No: 09 Release Date: 08/03/2022 TOTAL IGF-I ELISA IVD
 Page 5 of 5

NOTE: It is recommended that each laboratory should determine the reference Ansh Labs
range(s) for its own patient population. The results of this assay should be used 445 Medical Center Blvd.
in conjunction with other relevant and applicable clinical information. Webster, TX 77598-4217, U.S.A.

REFERENCES
1. Daughaday E, Rotwein P: Insulin like growth factors I and II. Peptide,
messenger ribonucleic acid and gene structures, serum and tissue
concentrations. Endocrine Rev 10:68-91, 1989.
2. Baxter RC, Martin JL, Beniac VA: High molecular weight insulin-like
growth factor binding protein complex. J Biol Chem 264:11843-11848,
1989.
3. Rechler M: Insulin-like growth factor binding proteins. Vit Horm 47:1-
114, 1993.
4. Zapf J, Hauri C, Waldvogel M, Froesch ER: Acute metabolic effects and
half-lives of intravenously administered insulin-like growth factors I and
II in normal and hypophysectomized rats. J Clin Invest 77:1768-1775,
1986.
5. Lee PDK, Rosenfeld RG: Clinical utility of insulin-like growth factor assays.
Pediatrician 14:154-161, 1987.
6. Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL: Insulin-like growth factors

ns h
ci de nly
I and II in evaluation of growth retardation. J Pediatr 109:428-433, 1986.

io it
at w
7. Lee PDK, Wilson DM, Rountree L, Hintz RL, Rosenfeld RG: Efficacy of

.
pe clu O
insulin-like growth factor I levels in predicting the response to

fic d
provocative growth hormone testing. Pediatr Res 27:45-51, 1990.

t s t in es
8. Soliman AT, Hassan AEHI, Aref MK, Hintz RL, Rosenfeld RG, Rogol AD:
ac er os
Serum insulin-like growth factors I and II concentrations and growth
ex ins rp

hormone and insulin responses to arginine infusion in children with

protein-calorie malnutrition before and after nutritional rehabilitation.
or e Pu

Pediatr Res 20:1122-1130, 1986.

9. Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Diamond FB. Jr, Rosenfeld
t f ag e
uc ck tiv

RG: Growth hormone receptor deficiency in Ecuador: Clinical and

biochemical phenotype in two populations. J Clin Endocrinol Metab
od a tra

76:417-423, 1993.
pr to p lus

10. Powell DR, Rosenfeld RG, Baker BK, Liu F, Hintz RL: Serum somatomedin
levels in adults with chronic renal failure: the importance of measuring
l
th er r I

insulin-like growth factor I (IGF-I) and IGF-II in acid-chromatographed

uremic serum. J Clin Endocrinol Metab 63:1186-1192, 1986.
ef Fo

11. Underwood LE, Murphy MG: Radioimmunoassay of the somatomedins.

IN Patrono C (ed): Radioimmunoassay in Basic and Clinical Pharmacology
(Handbook of Experimental Pharmacology vol 82) Springer-Verlag,
Heidelberg, 1987, pp 561-574.
R
e

12. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and

Biomedical Laboratories. Available
http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
13. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence
Bulletin 13 - Explosive Azide Hazard. Available http://
www.cdc.gov/niosh.
14. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000;
46: 1037–1038.

This assay is intended for in-vitro Diagnostic Use Only.

The Ansh Labs logo is a trademark of Ansh Labs.

Manufactured by:

Document No: IFU.AL.121 Revision No: 09 Release Date: 08/03/2022 TOTAL IGF-I ELISA IVD